Patient Safety Organizations: Voluntary Relinquishment for the Theator, Inc. PSO, 2790-2791 [2022-00906]
Download as PDF
<![CDATA[
jspears on DSK121TN23PROD with NOTICES1
2790
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
Æ That using D&B’s product is likely
to allow a business to have its
previously unreported commercial
payment experiences added to its credit
report;
Æ That D&B will actively assist a
business in adding its unreported
commercial payment experiences to its
credit report;
Æ That using D&B’s product is likely
to help a business build or improve its
credit report;
Æ The ease with which information or
payment experiences can be added to a
business’s credit report; and
Æ That D&B’s product is needed when
it is not, and that a product will enable
a prospective customer to have a
‘‘complete’’ file.
• Part I also features ancillary relief
relating to the challenged conduct by
prohibiting misrepresentations relating
to what payment experiences customers
can add, as well as to D&B’s renewal
and charging practices.
• Part II provides additional specific
relief relating to D&B’s renewal and
charging practices for products covered
under the Proposed Order, to make sure
that D&B makes clear disclosures about
renewals both before a customer
subscribes and during the period of the
subscription.
• Parts III and IV require D&B to make
certain disclosures to potential
customers of CreditBuilder products, so
that those potential customers can make
better informed decisions about whether
to purchase the products.
• Part V sets out specific
requirements for D&B to follow when a
business disputes information that D&B
reports about it. The requirements of
this Part V apply generally and are not
limited only to D&B customers.
• Part VI requires D&B to offer
refunds (or partial refunds) to certain
customers and former customers of
CreditBuilder products. Refund or
partial refund eligibility under the
Proposed Order will depend on
customers’ specific circumstances and
how they used or attempted to use their
CreditBuilder products.
• Part VII requires D&B to send
notices to all current customers of paid
products covered under the Proposed
Order that automatically renew.
Parts VIII through XII are reporting
and compliance provisions. Part VIII
mandates that D&B acknowledge receipt
of the Proposed Order and, for three
years, distribute the Proposed Order to
certain employees and agents and
secure acknowledgments from
recipients of the Proposed Order. Part IX
requires D&B to submit compliance
reports to the FTC one year after the
order’s issuance and submit additional
VerDate Sep<11>2014
16:58 Jan 18, 2022
Jkt 256001
reports when certain events occur. Part
X requires that, for 10 years, D&B
creates certain records and retain them
for at least 5 years. Part XI provides for
the FTC’s continued compliance
monitoring of D&B’s activity during the
Proposed Order’s effective dates. Part
XII is a provision ‘‘sunsetting’’ the
Proposed Order after 20 years, with
certain exceptions.
The purpose of this analysis is to
facilitate public comment on the
Proposed Order. It is not intended to
constitute an official interpretation of
the complaint or Proposed Order, or to
modify in any way the Proposed Order’s
terms.
By direction of the Commission.
April J. Tabor,
Secretary.
[FR Doc. 2022–00938 Filed 1–18–22; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Patient Safety Organizations:
Voluntary Relinquishment for the
Theator, Inc. PSO
Agency for Healthcare Research
and Quality (AHRQ), Department of
Health and Human Services (HHS).
ACTION: Notice of delisting.
AGENCY:
The Patient Safety and
Quality Improvement Final Rule
(Patient Safety Rule) authorizes AHRQ,
on behalf of the Secretary of HHS, to list
as a patient safety organization (PSO) an
entity that attests that it meets the
statutory and regulatory requirements
for listing. A PSO can be ‘‘delisted’’ by
the Secretary if it is found to no longer
meet the requirements of the Patient
Safety and Quality Improvement Act of
2005 (Patient Safety Act) and Patient
Safety Rule, when a PSO chooses to
voluntarily relinquish its status as a
PSO for any reason, or when a PSO’s
listing expires. AHRQ accepted a
notification of proposed voluntary
relinquishment from the Theator, Inc.
PSO, PSO number P0218, of its status as
a PSO, and has delisted the PSO
accordingly.
SUMMARY:
The delisting was effective at
12:00 Midnight ET (2400) on December
22, 2021.
ADDRESSES: The directories for both
listed and delisted PSOs are ongoing
and reviewed weekly by AHRQ. Both
directories can be accessed
DATES:
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
electronically at the following HHS
website: https://www.pso.ahrq.gov/listed.
FOR FURTHER INFORMATION CONTACT:
Cathryn Bach, Center for Quality
Improvement and Patient Safety, AHRQ,
5600 Fishers Lane, MS 06N100B,
Rockville, MD 20857; Telephone (toll
free): (866) 403–3697; Telephone (local):
(301) 427–1111; TTY (toll free): (866)
438–7231; TTY (local): (301) 427–1130;
Email: pso@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
Background
The Patient Safety Act, 42 U.S.C.
299b–21 to 299b–26, and the related
Patient Safety Rule, 42 CFR part 3,
published in the Federal Register on
November 21, 2008 (73 FR 70732–
70814), establish a framework by which
individuals and entities that meet the
definition of provider in the Patient
Safety Rule may voluntarily report
information to PSOs listed by AHRQ, on
a privileged and confidential basis, for
the aggregation and analysis of patient
safety work product.
The Patient Safety Act authorizes the
listing of PSOs, which are entities or
component organizations whose
mission and primary activity are to
conduct activities to improve patient
safety and the quality of health care
delivery.
HHS issued the Patient Safety Rule to
implement the Patient Safety Act.
AHRQ administers the provisions of the
Patient Safety Act and Patient Safety
Rule relating to the listing and operation
of PSOs. The Patient Safety Rule
authorizes AHRQ to list as a PSO an
entity that attests that it meets the
statutory and regulatory requirements
for listing. A PSO can be ‘‘delisted’’ if
it is found to no longer meet the
requirements of the Patient Safety Act
and Patient Safety Rule, when a PSO
chooses to voluntarily relinquish its
status as a PSO for any reason, or when
a PSO’s listing expires. Section 3.108(d)
of the Patient Safety Rule requires
AHRQ to provide public notice when it
removes an organization from the list of
PSOs.
AHRQ has accepted a notification of
proposed voluntary relinquishment
from the Theator, Inc. PSO to
voluntarily relinquish its status as a
PSO. Accordingly, the Theator, Inc.
PSO, P0218, was delisted effective at
12:00 Midnight ET (2400) on December
22, 2021.
More information on PSOs can be
obtained through AHRQ’s PSO website
at https://www.pso.ahrq.gov.
E:\FR\FM\19JAN1.SGM
19JAN1
Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices
Dated: January 12, 2022.
Marquita Cullom,
Associate Director.
[FR Doc. 2022–00906 Filed 1–18–22; 8:45 am]
BILLING CODE 4160–90–P
Prevention and the Agency for Toxic
Substances and Disease Registry.
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–00868 Filed 1–18–22; 8:45 am]
[FR Doc. 2022–00867 Filed 1–18–22; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Notice of Closed Meeting
Centers for Disease Control and
Prevention
[Docket No. CDC–2022–0003]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
DP22–001, Real-World Effectiveness of
Structured Lifestyle Interventions in
Preventing Type 2 Diabetes.
Date: March 23, 2022.
Time: 10:30 a.m.–6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
Jaya
Raman Ph.D., Scientific Review Officer,
National Center for Chronic Disease
Prevention and Health Promotion, CDC,
4770 Buford Highway, Mailstop S107–8,
Atlanta, Georgia 30341–3717,
Telephone: (770) 488–6511; Email:
JRaman@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
FOR FURTHER INFORMATION CONTACT:
jspears on DSK121TN23PROD with NOTICES1
2791
VerDate Sep<11>2014
17:56 Jan 18, 2022
Jkt 256001
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
DP22–002, Epidemiology of Lupus:
Longitudinal Studies in PopulationBased Cohorts.
Date: March 17, 2022.
Time: 11:00 a.m.–6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Jaya
Raman, Ph.D., Scientific Review Officer,
National Center for Chronic Disease and
Health Promotion, CDC, 4770 Buford
Highway, Mailstop S107–8, Atlanta,
Georgia 30341–3717, Telephone: (770)
488–6511, Email: JRaman@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Draft Policy Statement for Biosafety
Level 4 (BSL–4) and Animal BSL–4
(ABSL–4) Laboratory Verification;
Notice of Availability
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of availability and
comment.
AGENCY:
The Centers for Disease
Control and Prevention (CDC) in the
Department of Health and Human
Services (HHS) announces the opening
of a docket to obtain comment on a draft
policy statement regarding Biosafety
Level 4 (BSL–4)/Animal Biosafety Level
4 (ABSL–4) verification requirements.
The policy statement, once finalized,
will assist individuals and entities in
verifying that the facility design
parameters and operational procedures,
including heating, ventilation, and air
conditioning (HVAC) systems, in BSL–
4 and/or ABLS–4 laboratories are
functioning as intended to meet the
biosafety sufficiency requirement in the
HHS/CDC select agent regulations.
DATES: Submit written or electronic
comments by March 21, 2022.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2022–
0003, by either of the following
methods.
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Division of Select Agents and
Toxins, Centers for Disease Control and
Prevention, 1600 Clifton Road NE,
Mailstop H21–7, Atlanta, Georgia 30329.
Instructions: All submissions received
must include the Agency name and
Docket No. CDC–2022–0003. All
relevant comments received will be
posted without change to https://
www.regulations.gov, including any
personal information provided. Do not
send comments by email. CDC does not
accept comments by email.
Docket Access: For access to the
docket to read background documents
or comments received, or to download
SUMMARY:
E:\FR\FM\19JAN1.SGM
19JAN1
]]>Agencies
[Federal Register Volume 87, Number 12 (Wednesday, January 19, 2022)]
[Notices]
[Pages 2790-2791]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-00906]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Patient Safety Organizations: Voluntary Relinquishment for the
Theator, Inc. PSO
AGENCY: Agency for Healthcare Research and Quality (AHRQ), Department
of Health and Human Services (HHS).
ACTION: Notice of delisting.
-----------------------------------------------------------------------
SUMMARY: The Patient Safety and Quality Improvement Final Rule (Patient
Safety Rule) authorizes AHRQ, on behalf of the Secretary of HHS, to
list as a patient safety organization (PSO) an entity that attests that
it meets the statutory and regulatory requirements for listing. A PSO
can be ``delisted'' by the Secretary if it is found to no longer meet
the requirements of the Patient Safety and Quality Improvement Act of
2005 (Patient Safety Act) and Patient Safety Rule, when a PSO chooses
to voluntarily relinquish its status as a PSO for any reason, or when a
PSO's listing expires. AHRQ accepted a notification of proposed
voluntary relinquishment from the Theator, Inc. PSO, PSO number P0218,
of its status as a PSO, and has delisted the PSO accordingly.
DATES: The delisting was effective at 12:00 Midnight ET (2400) on
December 22, 2021.
ADDRESSES: The directories for both listed and delisted PSOs are
ongoing and reviewed weekly by AHRQ. Both directories can be accessed
electronically at the following HHS website: https://www.pso.ahrq.gov/listed.
FOR FURTHER INFORMATION CONTACT: Cathryn Bach, Center for Quality
Improvement and Patient Safety, AHRQ, 5600 Fishers Lane, MS 06N100B,
Rockville, MD 20857; Telephone (toll free): (866) 403-3697; Telephone
(local): (301) 427-1111; TTY (toll free): (866) 438-7231; TTY (local):
(301) 427-1130; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Background
The Patient Safety Act, 42 U.S.C. 299b-21 to 299b-26, and the
related Patient Safety Rule, 42 CFR part 3, published in the Federal
Register on November 21, 2008 (73 FR 70732-70814), establish a
framework by which individuals and entities that meet the definition of
provider in the Patient Safety Rule may voluntarily report information
to PSOs listed by AHRQ, on a privileged and confidential basis, for the
aggregation and analysis of patient safety work product.
The Patient Safety Act authorizes the listing of PSOs, which are
entities or component organizations whose mission and primary activity
are to conduct activities to improve patient safety and the quality of
health care delivery.
HHS issued the Patient Safety Rule to implement the Patient Safety
Act. AHRQ administers the provisions of the Patient Safety Act and
Patient Safety Rule relating to the listing and operation of PSOs. The
Patient Safety Rule authorizes AHRQ to list as a PSO an entity that
attests that it meets the statutory and regulatory requirements for
listing. A PSO can be ``delisted'' if it is found to no longer meet the
requirements of the Patient Safety Act and Patient Safety Rule, when a
PSO chooses to voluntarily relinquish its status as a PSO for any
reason, or when a PSO's listing expires. Section 3.108(d) of the
Patient Safety Rule requires AHRQ to provide public notice when it
removes an organization from the list of PSOs.
AHRQ has accepted a notification of proposed voluntary
relinquishment from the Theator, Inc. PSO to voluntarily relinquish its
status as a PSO. Accordingly, the Theator, Inc. PSO, P0218, was
delisted effective at 12:00 Midnight ET (2400) on December 22, 2021.
More information on PSOs can be obtained through AHRQ's PSO website
at https://www.pso.ahrq.gov.
[[Page 2791]]
Dated: January 12, 2022.
Marquita Cullom,
Associate Director.
[FR Doc. 2022-00906 Filed 1-18-22; 8:45 am]
BILLING CODE 4160-90-P
